http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 SAN DIEGO, Calif., November 12, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities... http://pharmalicensing.com/redirs/news_rss//public/news/view/499916/0/0/medicinova-reports-third-quarter-2009-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499916/0/0/medicinova-reports-third-quarter-2009-results Basel, November 12, 2009 - Novartis announced the availability of Prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/0/0/novartis-launches-prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/0/0/novartis-launches-prevacid FARMINGDALE, N.Y., November 12, 2009 -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and... http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/0/0/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries http://pharmalicensing.com/redirs/news_rss//public/news/view/499911/0/0/misonix-announces-new-distribution-agreement-for-saudi-arabia-and-other-middle-eastern-countries BOTHELL, WA, November 12, 2009 -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the three- and nine-month periods ended September 30, 2009. Net loss for the third quarter of 2009... http://pharmalicensing.com/redirs/news_rss//public/news/view/499912/0/0/mdrna-inc-announces-third-quarter-2009-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499912/0/0/mdrna-inc-announces-third-quarter-2009-financial-results SAN MATEO, CA, November 12, 2009 -- Nile Therapeutics, Inc. (NASDAQ: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced its third quarter... http://pharmalicensing.com/redirs/news_rss//public/news/view/499906/0/0/nile-therapeutics-reports-2009-third-quarter-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499906/0/0/nile-therapeutics-reports-2009-third-quarter-financial-results AVAL, QC, November 12, 2009 - LAB Research Inc. ("LAB Research" or the "Company") (TSX: LRI), a global Canadian-based non-clinical contract research organization, today announced its 2009 third... http://pharmalicensing.com/redirs/news_rss//public/news/view/499905/0/0/lab-research-announces-its-2009-third-quarter-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499905/0/0/lab-research-announces-its-2009-third-quarter-financial-results NEWTON, Mass., November 12, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that... http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement FORT LEE, N.J.-- November 12, 2009-- Neurologix, Inc. (OTCBB: NRGX) (the "Company"), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous... http://pharmalicensing.com/redirs/news_rss//public/news/view/499901/0/0/neurologix-announces-third-quarter-2009-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499901/0/0/neurologix-announces-third-quarter-2009-financial-results November 12, 2009 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and... http://pharmalicensing.com/redirs/news_rss//public/news/view/499900/0/0/champions-biotechnology-to-present-data-at-aacr-eortc-2009-regarding-the-predictability-of-biomerk-tumorgraft-tm-platform-to-guide-personalized-cancer-treatment-and-accelerate-oncology-drug-development http://pharmalicensing.com/redirs/news_rss//public/news/view/499900/0/0/champions-biotechnology-to-present-data-at-aacr-eortc-2009-regarding-the-predictability-of-biomerk-tumorgraft-tm-platform-to-guide-personalized-cancer-treatment-and-accelerate-oncology-drug-development Princeton, NJ and San Diego, CA, November 12, 2009--Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening... http://pharmalicensing.com/redirs/news_rss//public/news/view/499708/0/0/tobira-therapeutics-inc-announce-presentation-of-tbr-652-data-at-european-aids-conference http://pharmalicensing.com/redirs/news_rss//public/news/view/499708/0/0/tobira-therapeutics-inc-announce-presentation-of-tbr-652-data-at-european-aids-conference